Complementary and alternative medicine during cancer treatment: Beyond innocence

Oncologist

Volumn 11, Issue 7, 2006, Pages 732-741

  Tascilar, Metin ^a   De Jong, Floris A ^a   Verweij, Jaap ^a   Mathijssen, Ron H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CAM; Cancer; Herbs; Interactions; Internet; Regulation

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; NATURAL PRODUCT;

ADVERTIZING; ALTERNATIVE MEDICINE; CANCER; CANCER PATIENT; CANCER THERAPY; EDUCATION; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; INTERNET; LAW; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SOCIOECONOMICS; SUPPLEMENTATION;

COMPLEMENTARY THERAPIES; DECISION MAKING; HEALTH PLANNING GUIDELINES; HERB-DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 33746612104     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-7-732     Document Type: Review

References (99)

1. National Center for Complementary and Alternative Medicine (NCCAM). The Use of Complementary and Alternative Medicine in the United States. Available at http://nccam.nih.gov/news/camsurvey_fs1.htm. Accessed March 3, 2006.
2. Zollman C, Vickers A. What is complementary medicine? BMJ 1999;319:693-696.
3. British Medical Association (BMA). Complementary Medicine - New Approaches to Good Practice. Available at http://www.bma.org.uk/ap.nsf/content/ publicpetitioncam. Accessed March 3, 2006.
4. Cauffield JS. The psychosocial aspects of complementary and alternative medicine. Pharmacotherapy 2000;20:1289-1294.
5. Cassileth BR, Deng G. Complementary and alternative therapies for cancer. The Oncologist 2004;9:80-89.
6. Lafferty WE, Bellas A, Corage Baden A et al. The use of complementary and alternative medical providers by insured cancer patients in Washington State. Cancer 2004;100:1522-1530.
7. Cohen L, Warneke C, Fouladi RT et al. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 2004;100:2253-2260.
8. Yoo HJ, Ahn SH, Kim SB et al. Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life. Support Care Cancer 2005;13:826-833.
9. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-1575.
10. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002;35:166-173.
11. De Smet PA. Herbal medicine in Europe - relaxing regulatory standards. N Engl J Med 2005;352:1176-1178.
12. National Center for Complementary and Alternative Medicine (NCCAM). Funding Strategy: Fiscal Year 2006. Available at http://nccam.nih.gov/research/ strategy/2006.htm. Accessed March 3, 2006.
13. Sparreboom A, Cox MC, Acharya MR et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
14. Blumenthal RS, Becker DM, Yanek LR et al. Detecting occult coronary disease in a high-risk asymptomatic population. Circulation 2003;107:702-707.
15. Werneke U, Earl J, Seydel C et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-413.
16. McCune JS, Hatfield AJ, Blackburn AA et al. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004;12:454-462.
17. Maskarinec G, Shumay DM, Kakai H et al. Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 2000;6:531-538.
18. Morris KT, Johnson N, Homer L et al. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 2000;179:407-411.
19. Lee MM, Chang JS, Jacobs B et al. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 2002;92:1606-1609.
20. Burstein HJ, Gelber S, Guadagnoli E et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733-1739.
21. Richardson MA, Sanders T, Palmer JL et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
22. Patterson RE, Neuhouser ML, Hedderson MM et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 2002;8:477-485.
23. VandeCreek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 1999;5:71-76.
24. Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract 1999;48:453-458.
25. Vapiwala N, Mick R, DeNittis A et al. Initiation of complementary and alternative medical therapies (CAM) by cancer patients (pts) during radiation therapy (RT). Proc Am Soc Ther Radiat Oncol 2005;63(suppl 1):S451.
26. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-782.
27. Adams J, Sibbritt D, Young AF. Naturopathy/herbalism consultations by mid-aged Australian women who have cancer. Eur J Cancer Care (Engl) 2005;14:443-447.
28. Sibbritt DW, Adams J, Young AF. A longitudinal analysis of mid-age women's use of complementary and alternative medicine (CAM) in Australia, 1996-1998. Women Health 2004;40:41-56.
29. Girgis A, Adams J, Sibbritt D. The use of complementary and alternative therapies by patients with cancer. Oncol Res 2005;15:281-289.
30. Chrystal K, Allan S, Forgeson G et al. The use of complementary/ alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J 2003;116:U296.
31. Tough SC, Johnston DW, Verhoef MJ et al. Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Altern Ther Health Med 2002;8:54-56, 58-60, 62-64.
32. Tas F, Ustuner Z, Can G et al. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol 2005;44:161-167.
33. Molassiotis A, Fernadez-Ortega P, Pud D et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 2005;16:655-663.
34. Hyodo I, Amano N, Eguchi K et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23:2645-2654.
35. Cui Y, Shu XO, Gao Y et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat 2004;85:263-270.
36. Ashbury FD, Findlay H, Reynolds B et al. A Canadian survey of cancer patients' experiences: are their needs being met? J Pain Symptom Manage 1998;16:298-306.
37. Kosty MP. PC-SPES: hope or hype? J Clin Oncol 2004;22:3657-3659.
38. Straus SE. Herbal medicines - what's in the bottle? N Engl J Med 2002;347:1997-1998.
39. Vickers AJ, Kuo J, Cassileth BR. Unconventional anticancer agents: a systematic review of clinical trials. J Clin Oncol 2006;24:136-140.
40. Siddiqui IA, Adhami VM, Saleem M et al. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006;50:130-143.
41. Jian L, Xie LP, Lee AH et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108:130-135.
42. Gupta S, Ahmad N, Mohan RR et al. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999;59:2115-2120.
43. Cassileth BR. Complementary therapies: the American experience. Support Care Cancer 2000;8:16-23.
44. Cassileth BR, Lusk EJ, Strouse TB et al. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 1984;101:105-112.
45. Kronenberg F, Mindes J, Jacobson JS. The future of complementary and alternative medicine for cancer. Cancer Invest 2005;23:420-426.
46. Lis CG, Cambron JA, Grutsch JF et al. Self-reported quality of life in users and nonusers of dietary supplements in cancer. Support Care Cancer 2006;14:193-199.
47. Cassileth BR, Lusk EJ, Guerry D et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 1991;324:1180-1185.
48. Paltiel O, Avitzour M, Peretz T et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 2001;19:2439-2448.
49. Kappauf H, Leykauf-Ammon D, Bruntsch U et al. Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine/oncology and haematology. Support Care Cancer 2000;8:314-322.
50. Dy GK, Bekele L, Hanson LJ et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004;22:4810-4815.
51. Gupta D, Lis CG, Birdsall TC et al. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005;13:912-919.
52. Rakovitch E, Pignol JP, Chartier C et al. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 2005;90:139-148.
53. Helyer LK, Chin S, Chui BK et al. The use of complementary and alternative medicines among patients with locally advanced breast cancer - a descriptive study. BMC Cancer 2006;6:39.
54. De Smet PA. Herbal remedies. N Engl J Med 2002;347:2046-2056.
55. Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence. Eur Neuropsychopharmacol 1999;9:501-505.
56. de Jong FA, Engels FK, Mathijssen RH et al. Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol 2005;23:2886-2891.
57. Radbruch L, Nauck F. [A review of side effects and complications with cannabinoid treatment]. Schmerz 2003;17:274-279. German.
58. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 1992;42:181-191.
59. Singh H, Maskarinec G, Shumay DM. Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integr Cancer Ther 2005;4:187-194.
60. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms. Qualitative study of women's experiences. Can Fam Physician 1998;44:1271-1276.
61. De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004;76:1-17.
62. Benninger J, Schneider HT, Schuppan D et al. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999;117:1234-1237.
63. Vanherweghem JL, Depierreux M, Tielemans C et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-391.
64. Lord GM, Cook T, Arlt VM et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358:1515-1516.
65. Lampert N, Xu Y. Chinese herbal nephropathy. Lancet 2002;359:796-797.
66. Nortier JL, Martinez MC, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-1692.
67. Hazekamp A, Sijrier R, Verpoorte R et al. [Cannabis bought in the pharmacy is better]. Pharmaceutisch Weekblad 2005;140:402-405.
68. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-2211.
69. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175.
70. Mathijssen RH, Verweij J, de Bruijn P et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-1249.
71. Frye RF, Fitzgerald SM, Lagattuta TF et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-329.
72. Komoroski BJ, Parise RA, Egorin MJ et al. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005;11:6972-6979.
73. van Erp NP, Baker SD, Zhao M et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:7800-7806.
74. de Jong FA, Engels FK, Sparreboom A et al. Influence of medicinal cannabis (MC) on the pharmacokinetics (PK) of docetaxel (DOC) and irinotecan (CPT-11). Proc Am Assoc Cancer Res 2005;46.
75. Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: focus on mechanisms of induction. The Oncologist 2006;11:938-939.
76. Wang Z, Hamman MA, Huang SM et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420.
77. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002;54:661-669.
78. de Jong FA, Engels FK, Mathijssen RH et al. Medicinal cannabis in oncology practice: still a bridge too far? - In reply. J Clin Oncol 2005;23:7756.
79. Office of Medicinal Cannabis, Dutch Ministry of Health. Medicinal Cannabis: Information for Health Care Professionals, version 15 March, 2004. Available at http://www.cannabisbureau.nl/pdf/ basic%20text%20cannabis%20EN%20vs%2015%20Mar%2004%20.pdf. Accessed March 3, 2006.
80. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64:1943-1950.
81. Cohen MH. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatol Ther 2003;16:77-84.
82. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004;116:478-485.
83. Parkman CA. Regulatory issues in CAM. Case Manager 2004;15:26-29.
84. Fox S, Rainie L. Vital Decisions: How Internet Users Decide What Information to Trust When They or Their Loved Ones Are Sick. Washington, DC: Pew Internet & American Life Project, 2002.
85. Rice RE. Influences, usage, and outcomes of Internet health information searching: multivariate results from the Pew surveys. Int J Med Inform 2006;75:8-28.
86. Martin-Facklam M, Kostrzewa M, Schubert F et al. Quality markers of drug information on the Internet: an evaluation of sites about St. John's wort. Am J Med 2002;113:740-745.
87. Matthews SC, Camacho A, Mills PJ et al. The internet for medical information about cancer: help or hindrance? Psychosomatics 2003;44:100-103.
88. Schmidt K, Ernst E. Assessing websites on complementary and alternative medicine for cancer. Ann Oncol 2004;15:733-742.
89. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003;290:1505-1509.
90. Eysenbach G, Powell J, Kuss O et al. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA 2002;287:2691-2700.
91. Hyodo I, Eguchi K, Nishina T et al. Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan. Cancer 2003;97:2861-2868.
92. Bourgeault IL. Physicians' attitudes toward patients' use of alternative cancer therapies. CMAJ 1996;155:1679-1685.
93. Yates JS, Mustian KM, Morrow GR et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 2005;13:806-811.
94. Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol 2005;23:2590-2592.
95. Weitzman S. Alternative nutritional cancer therapies. Int J Cancer Suppl 1998;11:69-72.
96. Rosenthal DS, Dean-Clower E. Integrative medicine in hematology/oncology: benefits, ethical considerations, and controversies. Hematology (Am Soc Hematol Educ Program) 2005:491-497.
97. NIH Consensus Conference. Acupuncture. JAMA 1998;280:1518-1524.
98. Shen J, Wenger N, Glaspy J et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA 2000;284:2755-2761.
99. Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol 2000;1:176-180.